BR112016018044A2 - teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer - Google Patents

teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer

Info

Publication number
BR112016018044A2
BR112016018044A2 BR112016018044A BR112016018044A BR112016018044A2 BR 112016018044 A2 BR112016018044 A2 BR 112016018044A2 BR 112016018044 A BR112016018044 A BR 112016018044A BR 112016018044 A BR112016018044 A BR 112016018044A BR 112016018044 A2 BR112016018044 A2 BR 112016018044A2
Authority
BR
Brazil
Prior art keywords
predict
diagnostic test
drug response
molecular diagnostic
cancer prognosis
Prior art date
Application number
BR112016018044A
Other languages
English (en)
Inventor
Mccavigan Andrena
Gourley Charlie
Paul Harkin Denis
Patterson Fionnuala
Jellema Gera
E Keating Katherine
A Hill Laura
Kennedy Richard
Donegan Sinead
Deharo Steve
Davison Timothy
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Publication of BR112016018044A2 publication Critical patent/BR112016018044A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

métodos para selecionar se administrar um agente terapêutico antiangiogênico a um sujeito inclui etapas de medir os níveis de expressão de um ou mais biomarcadores selecionados a partir da tabela 2 ou tabela 3 em uma amostras a partir do sujeito; avaliar a partir dos níveis de expressão de um ou mais biomarcadores se a amostrar a partir do sujeito é positiva ou negativa para uma assinatura de biomarcador, em que se a amostra é positiva para a assinatura do biomarcador, um agente terapêutico antiangiogênico é contraindicado. métodos de prognostico e métodos de tratamento relatados são também fornecidos. a invenção é particularmente aplicável em cânceres de ovário e colorretal.
BR112016018044A 2014-02-07 2015-02-09 teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer BR112016018044A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461937224P 2014-02-07 2014-02-07
GBGB1409479.1A GB201409479D0 (en) 2014-05-28 2014-05-28 Molecular diagnostic test for cancer
PCT/GB2015/050352 WO2015118353A1 (en) 2014-02-07 2015-02-09 Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer

Publications (1)

Publication Number Publication Date
BR112016018044A2 true BR112016018044A2 (pt) 2018-02-20

Family

ID=51177582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016018044A BR112016018044A2 (pt) 2014-02-07 2015-02-09 teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer

Country Status (10)

Country Link
US (1) US10280468B2 (pt)
EP (1) EP3102700A1 (pt)
JP (1) JP2017506506A (pt)
KR (1) KR20160117606A (pt)
CN (1) CN106164296A (pt)
AU (1) AU2015213844A1 (pt)
BR (1) BR112016018044A2 (pt)
CA (1) CA2938807A1 (pt)
GB (1) GB201409479D0 (pt)
WO (1) WO2015118353A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11568982B1 (en) 2014-02-17 2023-01-31 Health at Scale Corporation System to improve the logistics of clinical care by selectively matching patients to providers
US10650325B2 (en) * 2015-07-31 2020-05-12 Microsoft Technology Licensing, Llc Deterministic message distribution
US10496691B1 (en) 2015-09-08 2019-12-03 Google Llc Clustering search results
WO2018062862A1 (ko) * 2016-09-28 2018-04-05 가톨릭대학교 산학협력단 신장암 환자의 예후 진단 및 치료 전략 결정용 성별 특이적 마커
WO2018124153A1 (ja) * 2016-12-28 2018-07-05 公益財団法人がん研究会 抗ｖｅｇｆｒ－２抗体医薬品の治療効果を予測するバイオマーカー、検査方法、及び検査キット
CN107301328B (zh) * 2017-05-19 2021-04-06 浙江工业大学 基于数据流聚类的癌症亚型精准发现与演化分析方法
DE112018002990T5 (de) * 2017-06-13 2020-04-02 Bostongene Corporation Systeme und verfahren zum erzeugen, visualisieren und klassifizieren von molekularen funktionellen profilen
JP6977965B2 (ja) * 2017-10-26 2021-12-08 公立大学法人福島県立医科大学 卵巣癌組織型鑑別方法
CN110880356A (zh) * 2018-09-05 2020-03-13 南京格致基因生物科技有限公司 对卵巢癌进行筛查、诊断或风险分级的方法和装置
EP3874274B1 (en) * 2018-10-31 2024-01-03 Regents of the University of Minnesota Methods for predicting a response to bevacizumab or platinum-based chemotherapy or both in patients with ovarian cancer
US11610679B1 (en) 2020-04-20 2023-03-21 Health at Scale Corporation Prediction and prevention of medical events using machine-learning algorithms
CN112164474A (zh) * 2020-07-14 2021-01-01 中国矿业大学 一种基于自表达模型的药物敏感性预测方法
CA3213049A1 (en) * 2021-03-25 2022-09-29 Laura E. BENJAMIN Targeted therapies in cancer
CN113667752A (zh) * 2021-09-09 2021-11-19 菲思特(上海)生物科技有限公司 一种用于柔红霉素代谢标志物的检测试剂盒及其检测方法和应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6998234B2 (en) 2000-11-03 2006-02-14 Oncotech, Inc. Methods for cancer prognosis and diagnosis relating to tumor vascular endothelial cells
CN1829741A (zh) 2003-05-30 2006-09-06 健泰科生物技术公司 利用抗－vegf抗体的治疗
US7659062B2 (en) 2003-06-03 2010-02-09 The Board of Trustee of the University of Arkansas System Gene expression profiling of uterine serous papillary carcinomas and ovarian serous papillary tumors
CN1922332B (zh) 2003-12-31 2013-06-12 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20080113874A1 (en) 2004-01-23 2008-05-15 The Regents Of The University Of Colorado Gefitinib sensitivity-related gene expression and products and methods related thereto
CA2563074C (en) 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
BRPI0511088A (pt) 2004-05-14 2007-12-26 Monica Nister identificação e caracterização de um subconjunto de glioblastomas sensìveis ao tratamento com imatinib
BRPI0513589A (pt) 2004-07-23 2008-05-13 Astrazeneca Ab método para selecionar um mamìfero tendo ou suspeito de ter um tumor para tratamento com uma droga de receptor de erbb
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US7862995B2 (en) * 2004-12-10 2011-01-04 Targeted Molecular Diagnostics Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
EP1937837A2 (en) 2005-07-29 2008-07-02 Siemens Healthcare Diagnostics Inc. Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
US8445198B2 (en) 2005-12-01 2013-05-21 Medical Prognosis Institute Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
EP1963862A4 (en) 2005-12-05 2010-03-03 Merck & Co Inc METHODS FOR PREDICTING REACTION TO TREATMENT FROM EXPRESSION PROFILES OF PROTEIN AND TRANSCRIPTIONAL BIOMARKERS
EP2363711A1 (en) 2006-01-27 2011-09-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0716944A2 (pt) 2006-09-19 2013-09-17 Novartis Ag biomarcadores de modulaÇço alvo, eficÁcia, diagnàstico, e/ou prognàstico para inibidores de raf
CA2694281A1 (en) 2007-08-13 2009-02-19 Almac Diagnostics Limited A 3'-based sequencing approach for microarray manufacture
MX2010005057A (es) 2007-11-09 2010-05-19 Genentech Inc Metodos y composiciones para uso de diagnostico en pacientes de cancer.
JP2011525106A (ja) 2008-06-04 2011-09-15 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 瀰漫性ｂ大細胞型リンパ腫のマーカーおよびその使用方法
CA2726811C (en) 2008-06-06 2019-11-26 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Survival predictor for diffuse large b cell lymphoma
KR20110052627A (ko) 2008-07-16 2011-05-18 다나-파버 캔서 인스티튜트 인크. 전립선암과 관련된 시그너처 및 ｐｃ결정인자 및 그의 사용 방법
WO2010010153A1 (en) 2008-07-23 2010-01-28 F. Hoffmann-La Roche Ag Identification of subjects being susceptible to anti-angiogenesis therapy
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
WO2010088688A2 (en) 2009-02-02 2010-08-05 Biotheranostics, Inc. Diagnosis of in situ and invasive breast cancer
US10179936B2 (en) 2009-05-01 2019-01-15 Genomic Health, Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US7615353B1 (en) * 2009-07-06 2009-11-10 Aveo Pharmaceuticals, Inc. Tivozanib response prediction
ES2530732T3 (es) 2009-09-17 2015-03-05 Hoffmann La Roche Procedimientos de diagnóstico para el cáncer de pulmón
KR20130115250A (ko) 2010-09-15 2013-10-21 알막 다이아그노스틱스 리미티드 암에 대한 분자적 진단 테스트
WO2012092336A2 (en) * 2010-12-28 2012-07-05 Caris Mpi, Inc. Molecular profiling for cancer
US10260097B2 (en) 2011-06-02 2019-04-16 Almac Diagnostics Limited Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
CN104203268A (zh) * 2012-01-13 2014-12-10 霍夫曼-拉罗奇有限公司 用于识别适于用vegf拮抗剂治疗的患者的生物标记物
EP2925885B1 (en) * 2012-12-03 2020-02-05 Almac Diagnostic Services Limited Molecular diagnostic test for cancer

Also Published As

Publication number Publication date
WO2015118353A1 (en) 2015-08-13
US20170073761A1 (en) 2017-03-16
JP2017506506A (ja) 2017-03-09
CA2938807A1 (en) 2015-08-13
GB201409479D0 (en) 2014-07-09
US10280468B2 (en) 2019-05-07
CN106164296A (zh) 2016-11-23
KR20160117606A (ko) 2016-10-10
AU2015213844A1 (en) 2016-09-15
EP3102700A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
BR112017009159A2 (pt) métodos e biomarcadores para predizer a eficácia e avaliação de um tratamento com agonista de ox40
MX2018008421A (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
BR112015023894A2 (pt) sistema e método para determinação de propriedades de uma amostra
BR112016010510A2 (pt) método, arranjo e uso do mesmo
BR112018070971A2 (pt) métodos e kits para a diagnose e estratificação de risco de pacientes com isquemia
BR112015018912A2 (pt) método e dispositivo para identificar comportamento de usuário
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
WO2015094996A3 (en) Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
BR112017018008A2 (pt) ?métodos de prognóstico e/ou diagnóstico do câncer, para determinação da dosagem de um produto, para adaptar a dosagem de um produto, para determinar os efeitos benéficos e/ou adversos de uma substância, para identificar um paciente como respondedor a um tratamento, para identificar um paciente como não respondedor a um tratamento, para tratar o câncer, meios para prognosticar e/ou diagnosticar, kit, uso dos meios e dispositivo para a identificação de câncer?
MX2013005067A (es) Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
BR112016004963A2 (pt) biomarcadores para determinação precoce de uma resposta crítica ou de risco de vida para resposta de tratamento e/ou doença
BR112018073178A2 (pt) método, matriz e uso dos mesmos
BR112016024143A2 (pt) tratamento de câncer
BR112017008218A2 (pt) métodos e composições para diagnóstico e prognóstico de lesão renal e insuficiência renal
WO2015073896A3 (en) Biomarkers for psma targeted therapy for prostate cancer
BR112018000463A2 (pt) uso de capacitância para detectar pressão de toque
BR112016012792A2 (pt) Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras
WO2018097614A3 (ko) 유방암 환자의 화학치료 유용성 예측 방법

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2552 DE 03-12-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]